Rodent studies indicate that HDAC activity increases with age and in models of AD, and that this is associated with decreases synaptic plasticity (43); therefore, HDAC inhibitors, such as SCFAs, may have a protective effect. Here, HDAC9 is linked to Alzheimer disease.